Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis
Sponsor: Telios Pharma, Inc.
Summary
In this prospective, Phase 2, randomized, double-masked, vehicle controlled study, approximately 66 eligible subjects will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally. The study comprises of a screening and treatment period using the conjunctival allergen challenge model to evaluate TL-925 for the treatment of allergic conjunctivitis.
Official title: A Single-Center, Randomized, Double-masked, Vehicle-controlled Phase 2 Study Evaluating the Safety and Efficacy of TL-925 Ophthalmic Emulsion 0.1% Compared to Vehicle for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (Ora-CAC®) Model
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
66
Start Date
2024-10-03
Completion Date
2024-12-10
Last Updated
2024-11-13
Healthy Volunteers
No
Conditions
Interventions
TL-925
TL-925 is an eye drop.
Placebo
The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.
Locations (1)
Telios Investigative Site
Memphis, Tennessee, United States